Now is an ideal time for small biotechs to ink that perfect deal with big pharma, attendees heard at the recently held Biotrinity conference in Oxfordshire, UK."The whole pharma industry is hungry for deals, in particular for Phase III compounds, as there is a shortage of drugs in pipelines,” said Rob Hockney, director of alliance management, Global Discovery Alliances at AstraZeneca. >>> Discuss This Story
